Other · Cytotoxic · developed by Nuvation Bio
NUV-1511 is a drug-drug conjugate made of an undisclosed tumor-targeting agent linked to an undisclosed chemotherapeutic agent. The targeting agent binds an undisclosed receptor expressed on certain tumor types, and the chemotherapeutic agent kills cancer cells by an mechanism not yet known. It is studied in advanced solid tumors, HER2-negative breast cancer, metastatic castration-resistant prostate cancer, pancreatic cancer, and platinum-resistant ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06334432 | Phase 1/2 | Advanced Solid Tumor | Active not recruiting | NUVB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Pancreatic CancerPlatinum-resistant Ovarian Cancer (PROC)
See NUVB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NUVB catalysts and pipeline →